Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

JIN-YUAN SHIHLuo, Yung-HungYung-HungLuoChang, Gee-ChenGee-ChenChangChang, John Wen-ChengJohn Wen-ChengChangWang, Chin-ChouChin-ChouWangYang, Tsung-YingTsung-YingYangFang, Wei-TseWei-TseFangShau, Wen-YiWen-YiShau2024-02-232024-02-232024-01-080929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/639919Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease progression despite prior treatment with ALK tyrosine kinase inhibitors (TKIs) was assessed. Herein, we report real-world clinical outcomes of lorlatinib-treated patients with ALK-positive advanced NSCLC who were heavily pretreated and progressed on first- and second-generation ALK-TKIs, in a Taiwanese population under the lorlatinib expanded access program (EAP).enALK; Lorlatinib; NSCLCReal-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancerjournal article10.1016/j.jfma.2023.12.019381953172-s2.0-85181947015https://api.elsevier.com/content/abstract/scopus_id/85181947015